What is the feasibility and acceptability of conducting a randomised controlled trial evaluating a healthcare professional-supported, self-management intervention for people suffering from fatigue after critical illness?

开始日期2025-04-15

申办/合作机构

Oxford Brookes University

NCT06551493

/ RecruitingN/AIIT

The Assessment of Postnatal Perineal Wound: Perspectives of Midwives and Women.

Around 85% of women who give birth vaginally experience a perineal wound, which could be a tear or an incision between the vaginal opening and the anus. Despite that, there is often insufficient exploration of how postnatal perineal wound assessment is conducted in healthcare research.
Clinical guidelines from the National Institute for Health and Care Excellence (NICE) touch on the typical signs of wound infection but do not offer detailed guidance on the execution of perineal assessment. Existing research evidence is mostly focused on long-term complications, management of perineal trauma immediately after birth or severe perineal trauma. The limited research on perineal wound care highlights how poor communication and information provision harm women at a physical and psychological level, negatively affecting daily tasks such as caring for their newborns.
Although there have been few studies examining women's or midwives' perspectives on perineal wound assessment in the context of uncomplicated wounds, their perspectives have never been jointly investigated to produce a comprehensive overview. Moreover, no research has had a clinical focus, investigating how the assessment is conducted in practice and what informs this practice, except from women's reports of perceived sub-standard care received.
Therefore, this proposed research is clinically grounded and aims to explore women's and midwives' perspectives on postnatal perineal wound assessment. This is needed to identify evidence-based practices, or lack thereof, in order to determine ways in which the experience can be improved for women and to have a more positive impact on their wellbeing.
Eight to ten pairs of midwives-women will be first observed whilst the routine assessment is conducted to understand what happens during this episode of care, and then they will be separately interviewed within a few days to gather further understanding. Recruitment will be in a single centre, which is a tertiary unit in the UK.

开始日期2024-11-20

申办/合作机构

Oxford Brookes University

ISRCTN89882877

/ RecruitingN/A

A twelve-week randomised, placebo-controlled study on the effect of Reducose® on glucose, insulin, haemoglobin A1c, satiety, body composition, lipid profile, inflammatory markers and changes in gut microbiome in an overweight population. REMET (Reducose Metabolic Trial)

开始日期2024-10-28

申办/合作机构

Phynova Group Ltd.

[+1]

100 项与 Oxford Brookes University 相关的临床结果

登录后查看更多信息

0 项与 Oxford Brookes University 相关的专利（医药）

登录后查看更多信息

4,295

项与 Oxford Brookes University 相关的文献（医药）

2025-12-31·GYNECOLOGICAL ENDOCRINOLOGY

Effect of combined aerobic exercise and resistance training on postmenopausal women with type 2 diabetes: a systematic review and meta-analysis

Review

作者: Soares Júnior, Jose Maria ; Chagas, André dos Santos ; Porto, Andrey Alves ; Valenti, Vitor Engracia ; de Souza, Ingrid Soares ; Raimundo, Rodrigo Daminello ; Zangirolami-Raimundo, Juliana ; Chedraui, Peter ; Sorpreso, Isabel Cristina Esposito ; Garner, David M.

BACKGROUND:

There is no strong evidence demonstrating whether or not aerobic exercise in conjunction with resistance exercise improves metabolic diabetes markers in postmenopausal women.

OBJECTIVE:

To evaluate the effect of aerobic exercise and resistance training on metabolic markers in postmenopausal women with type 2 diabetes mellitus (T2DM) by means of a systematic review and meta-analysis.

METHODS:

The searches were completed using EMBASE, MEDLINE/PubMed, Scopus and Web of Science databases. This study included non-blinded, single or double-blinded randomized control trials and postmenopausal women diagnosed with T2DM. The imposed intervention was aerobic exercise plus any training protocol to strengthen muscle groups for resistance intervention. The outcomes of interest were the blood glucose levels, insulin secretion, homeostasis model assessment-insulin resistance index (HOMA-IR) and glycated hemoglobin (HbA1c). Risk of Bias tools and GRADE were obligatory.

RESULTS:

Three studies were included (83 participants). Exercise intervention ranged between two to four days per week. Compared to the control group, in the group submitted to aerobic exercise + resistance training, no significant change was noted for HbA1c (subtotal = mean difference - 0.35 [95% CI: -0.85, 0.15], p = .17, and heterogeneity = 0%) (GRADE: very low), nevertheless, HOMA-IR index was significantly improved (subtotal = mean difference -0.52 [95% CI: -0.99, -0.05], p = .03, and heterogeneity = 0%) (GRADE: very low).

CONCLUSION:

Despite the very low certainty found in the quality of evidences, our analysis showed that aerobic exercise along with strength exercise seems to improve some metabolic diabetes markers in postmenopausal women with T2DM. There is a need for further studies to support our preliminary findings.

2025-09-01·JOURNAL OF CHILD LANGUAGE

Testing the relationship between preferences for infant-directed speech and vocabulary development: A multi-lab study

Article

作者: Alshakhori, Mohammed K ; Ota, Mitsuhiko ; Potter, Christine E ; Bergmann, Christina ; Mayor, Julien ; Ryjova, Yana ; Rennels, Jennifer L ; Tsui, Angeline S M ; Ko, Eon-Suk ; Boyce, Veronica ; Muñoz, Luis E ; Machon, Lauren C ; Kiley Hamlin, J ; Soderstrom, Melanie ; Fritzsche, Tom ; Frank, Michael C ; Davies, Catherine ; Hay, Jessica F ; Byers-Heinlein, Krista ; Skarabela, Barbora ; Rocha-Hidalgo, Joscelin ; Seidl, Amanda ; Gonzalez-Gomez, Nayeli ; Anderson, Laura ; Werker, Janet F ; Kartushina, Natalia ; Kammermeier, Marina ; Gampe, Anja ; Al-Hoorie, Ali H ; Havron, Naomi ; Kim, Hyunji ; Nave, Karli M ; Jessop, Andrew ; Durrant, Samantha ; Paulus, Markus ; Cashon, Cara ; Lew-Williams, Casey ; Hannon, Erin E ; Black, Alexis K ; Olesen, Nonah M ; Martin, Alia ; Bochynska, Agata

Abstract:

From early on, infants show a preference for infant-directed speech (IDS) over adult-directed speech (ADS), and exposure to IDS has been correlated with language outcome measures such as vocabulary. The present multi-laboratory study explores this issue by investigating whether there is a link between early preference for IDS and later vocabulary size. Infants’ preference for IDS was tested as part of the ManyBabies 1 project, and follow-up CDI data were collected from a subsample of this dataset at 18 and 24 months. A total of 341 (18 months) and 327 (24 months) infants were tested across 21 laboratories. In neither preregistered analyses with North American and UK English, nor exploratory analyses with a larger sample did we find evidence for a relation between IDS preference and later vocabulary. We discuss implications of this finding in light of recent work suggesting that IDS preference measured in the laboratory has low test-retest reliability.

2025-09-01·ULTRASONICS SONOCHEMISTRY

An integrated numerical modelling framework for simulation of the multiphysics in sonoprocessing of materials

Article

作者: Li, Lianxia ; Mi, Jiawei ; Xiang, Kang ; Eskin, Dmitry ; Qin, Ling ; Tzanakis, Iakovos

We have designed, developed, and integrated a comprehensive mathematical and numerical modelling framework for simulations of the complex physics and highly dynamic phenomena that occur across different length and time scales in the processes of sonochemistry and sonication of materials. The framework comprises three interconnected sub-models: (1) a bubble oscillation and implosion model, (2) a shock wave emission and propagation model, and (3) a wave-structure interaction (WSI) model. Firstly, we described in detail the governing equations, numerical schemes, boundary and initial conditions used in each sub-model with a particular emphasis on the data mapping methods for numerically linking the three sub-models together. Then, we present a number of simulation cases to demonstrate the power and usefulness of the model. We also did systematic model validation and calibration using the in-situ and real-time collected big X-ray image data. This is the first time such comprehensive and high-fidelity numerical models have been achieved for sonoprocessing of materials. Complementary to the most advanced in-situ and operando experiments, the integrated model is an indispensable modelling tool for computational studies and optimizations of the ultrasound-assisted chemical synthesis and sonoprocessing of materials.

项与 Oxford Brookes University 相关的新闻（医药）

2023-12-14

·生物制品圈

杆状病毒表达载体系统 - 杆状病毒基因组修饰

杆状病毒表达系统作为真核细胞表达系统的一种，以其表达量大、可携带较大的基因片段及表达产物功能活性好等方面的优势得到了广泛的应用。对于表达外源基因的亲本杆状病毒基因组的修饰，多数都是在多角体基因位点，其余的154个可读框不变，随后插入外源基因。尽管杆状病毒的一些基因功能已经确定，但是它们的表达产物是否对重组蛋白表达产量有影响还不清楚。基本上，多数杆状病毒表达载体都是多角体基因缺失型的，包含一个外源基因，且能够产生病毒感染昆虫完整的病理学过程。杆状病毒编码几丁质酶和组织蛋白酶，其作用是液化昆虫幼虫宿主，研究发现缺失这些基因可能提高重组蛋白的产量。英国Oxford Expression Technologies公司（OET）是全球领先的杆状病毒表达系统供应商，于2007年由牛津布鲁克斯大学及自然环境研究委员会联合成立，OET公司向全球医药公司及科研用户提供这种基因缺失的高效的杆状病毒表达系统- flashBAC及其相关产品。flashBAC杆状病毒表达系统使得杆状病毒的表达更快速，更灵活，更简单，与传统的表达系统比较，不仅更加省时省力，具有更高的蛋白产量，并且具有更高的蛋白活性和稳定性，尤其适用于难表达的蛋白。flashBAC表达系统介绍flashBAC系列是一个全新的生产重组杆状病毒技术平台，本系统缺失了杆状病毒基因组DNA必需基因的一部分，用一段人工合成的基因（bacterial artificial chromosome ，BAC) 替代多角体编码区，改造后的环状杆状病毒能在大肠杆菌中复制却不能在昆虫细胞中复制，当与携带目的基因的转移载体共转染昆虫细胞后，通过同源重组重新获得必需基因片段并将目的基因转移到杆状病毒基因组中，只有发生同源重组的病毒才能在昆虫细胞中复制，从而实现在昆虫细胞中一步法生产重组病毒，不需进行繁琐的空斑筛选工作。与传统的表达系统比较，不仅更加省时省力，而且具有更高的蛋白产量，尤其适用于难表达的蛋白，并且具有更高的蛋白活性和稳定性。本系统和常用转移载体兼容。优点：操作简单在昆虫细胞中一步法生产重组病毒无需筛选纯化重组病毒蛋白表达效率高，尤其适于分泌蛋白，膜蛋白的表达适合于高通量自动化生产和常用转移载体兼容flashBAC试剂盒删除了杆状病毒基因组上的chiA编码基因，chiA定位于内质网，严重影响分泌通道效率。chiA的删除提高了分泌蛋白和膜蛋白的表达量，最高可提高60倍。flashBACGOLD 试剂盒去除了杆状病毒基因组中的chiA和v-cath编码基因，提高了重组蛋白分泌效率和胞内蛋白的稳定性，可以使任何蛋白超水平表达，包括分泌性蛋白，细胞膜蛋白，或者特别容易降解的蛋白。flashBACULTRA是flashBAC技术的最新进展，包括如上所述的去除杆状病毒基因组中的chiA和v-cath编码基因，同时还去除了p10, p74和p26基因，P10启动子和polh启动子在起始区共享12个核苷酸，和polh启动子竞争，删除p10，提高了polh启动子的活性，从转录开始提高重组蛋白表达水平，是大量难以表达蛋白研究的很好选择。flashBACPRIME结合了flashBAC牛痘病毒表达系统的简单性与增加产量的病毒样颗粒(VLPs)。flashBACPRIME基于原始AcMNPV基因组，没有其它flashBAC系列载体所具有的任何基因缺失特征。因此，flashBACPRIME的细胞内裂解在感染后期发生，这有助于释放并在感染细胞质或核中形成后的纯化VLPs(或其他蛋白质)。当表达病毒样颗粒时，我们建议使用从毛癣菌属(Trichoplusia ni)细胞系产生的重组病毒。flashBAC™ selection试剂盒要么包含三个试剂盒flashBAC™, flashBAC™ GOLD和 flashBAC™ ULTRA (Box 1)或者包含三个试剂盒flashBAC™, flashBAC™ GOLD, flashBAC™ ULTRA 和flashBAC™ PRIME (Box 2)，可以根据需要选择。参考文献https://www.oetltd.com/识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

引进/卖出

2023-09-27

·BioSpace

PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the appointment of Robert Lyne as Chief Portfolio Officer. Robert brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience. Robert is expected to join PureTech by early January 2024. This press release features multimedia. View the full release here: PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer (Photo: Business Wire) “We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients,” said Daphne Zohar, Founder and Chief Executive Officer of PureTech. “His extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech’s own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties.” Mr. Lyne joins PureTech from Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as General Counsel and Chief Operating Officer before being appointed Chief Executive Officer in April 2021. He began his career as a lawyer at international law firm Bird & Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. He has worked on over 80 venture capital financings in Europe and North America as well as multiple trade exits and IPOs. As an experienced UK plc executive, Mr. Lyne has broad experience formulating and implementing corporate strategy. Mr. Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University. “I am delighted to be joining the management team at PureTech during such an exciting time in the Company’s growth,” said Mr. Lyne. “As pioneers of the hub-and-spoke model in the biotechnology sector, PureTech’s approach is aligned with my own experience and ambitions. They are highly innovative in their approach to both science and business, which has led to the team delivering an impressive track record of developing new therapies with transformational potential. I look forward to working with the skilled team at PureTech and its outstanding network of advisors to further drive the Company forward.” About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that is expected to be filed soon for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on Twitter @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those statements that relate to our expectations around our product candidates and approach towards addressing major diseases, and our future prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on businesswire.com: Contacts PureTech Public Relations publicrelations@puretechhealth.com Investor Relations IR@puretechhealth.com EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000 ben.atwell@FTIconsulting.com U.S. Media Nichole Sarkis +1 774 278 8273 nichole@tenbridgecommunications.com Source: PureTech Health plc Smart Multimedia Gallery Photo PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer (Photo: Business Wire) Logo View this news release and multimedia online at:

高管变更并购

2023-04-27

·生物谷

Science：新的发现挑战了我们对神经系统及其进化的理解

一项新的研究提出了神经网络结构的基本差异，挑战了我们以前对神经系统的进化以及它们如何传递信息的理解。相关研究结果发表在2023年4月21日的Science期刊上。一项新的研究提出了神经网络结构的基本差异，挑战了我们以前对神经系统的进化以及它们如何传递信息的理解。相关研究结果发表在2023年4月21日的Science期刊上，论文标题为“Syncytial nerve net in a ctenophore adds insights on the evolution of nervous systems”。具体而言，由挪威卑尔根大学迈克尔-萨斯中心的Pawel Burkhardt和英国牛津布鲁克斯大学的Maike Kittelmann领导的一个研究团队利用先进技术，揭示了作为最古老的动物品系之一的栉水母（ctenophores）的神经系统连接性。通过三维电子显微镜重建它的神经网络中的神经元，他们发现了一个非凡的架构：一个连续的神经网络。这些发现挑战了我们对神经系统及其进化的理解。改变神经生物学理论自从19世纪科学家Santiago Ramóny Cajal和Fridtjof Nansen的研究工作以来，神经生物学研究一直是通过神经元学说的视角来解释的。这一理论指出，神经系统是由离散的细胞组成的。Camillo Golgi挑战了这一理论，提出了神经系统内的神经元是作为一个连续的网络连接的观点。Cajal和Golgi因其非凡的发现在1906年分享了诺贝尔奖，尽管他们在整个职业生涯中是激烈的竞争对手。 Cajal的理论最终被证明是正确的，他通过在20世纪50年代发明的电子显微镜确定了神经元连接，即所谓的突触，从而推翻了Golgi的理论。如今，这些新的发现证实Golgi的理论也是正确的。为什么是栉水母？栉水母是迷人的生物，已经在世界海洋中生活了大约6亿年。当第一批动物进化时，栉水母是地球上最早的动物品系之一。在神经元和神经系统的早期进化中，可能建立了多种制造神经系统的方法。以前试图描述栉水母神经系统的连接性已被证明是困难的，因为这类生物是非常脆弱的，研究它们的解剖结构是非常具有挑战性的。应用新技术激发了好奇心 Burkhardt与三维电子显微镜专家Kittelmann合作，发现栉水母神经网络中的单个神经元通过将它的称为神经突（neurite）的神经突起相互融合，形成了一个小型的神经网络。出于对探索这种不规则性的好奇，Pawel和Maike收集了一个更大的三维数据集。Maike说，“在牛津布鲁克斯大学的生物成像中心，我们有一个串行块面扫描电子显微镜（Serial Block Face SEM），它可以自动收集一种动物的数百张图像。我们如今拥有的数据集之一包括五个神经网络神经元及其广泛分支的神经突。”重建这些细胞发现了一个非凡的结构：它们形成了一个连续的神经网络。图片来自Science, 2023, doi:10.1126/science.ade5645。 Burkhardt说，“我们发现栉水母的神经网络与刺胞动物（cnidarians）和其他动物的神经网络之间存在根本性的差异。这非常令人兴奋。人们可能会争论：它是一种神经系统吗？” 尽管这种独特的结构，栉水母的神经网络显示了在神经系统中发现的关键特征，如神经肽和产生膜电位的离子通道。这些发现意味着什么？对栉水母神经网络的这种表征有可能提供关于神经系统进化起源的关键信息。通过揭示栉水母神经元的独特和不寻常的运作原理，这些作者提供了一种思考神经系统架构的新方法，从而为新时期的比较神经科学研究铺平道路。（生物谷 Bioon.com）参考资料： Pawel Burkhardt et al. Syncytial nerve net in a ctenophore adds insights on the evolution of nervous systems. Science, 2023, doi:10.1126/science.ade5645.

100 项与 Oxford Brookes University 相关的药物交易

登录后查看更多信息

100 项与 Oxford Brookes University 相关的转化医学

登录后查看更多信息